Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II

BACKGROUND: Mucopolysaccharidosis type II (MPS II, Hunter syndrome), is caused by a deficiency of iduronate-2-sulfatase (IDS). Despite the therapeutic effect of intravenous enzyme replacement therapy (ERT), the central nervous system (CNS) defects persist because the enzyme cannot cross the blood-br...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Sung Yoon, Lee, Jeehun, Ko, Ah-Ra, Kwak, Min Jung, Kim, Sujin, Sohn, Young Bae, Park, Sung Won, Jin, Dong-Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628320/
https://www.ncbi.nlm.nih.gov/pubmed/26520066
http://dx.doi.org/10.1186/s13023-015-0356-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628320/
https://www.ncbi.nlm.nih.gov/pubmed/26520066
http://dx.doi.org/10.1186/s13023-015-0356-0

Ejemplares similares